However, gene expression analysis shows that Myo1C is predominantly downregulated in several types of cancer, with ovarian cancer being the most prevalent (50% of all cancer cases have reduced expression of Myo1C), followed by the large intestine, kidney, lung, urinary tract, and breast cancers. Here, MYO1C is linked to cancer.